有利风险Gleason 3+4与低风险Gleason 6前列腺癌的病理和肿瘤学结局比较:主动监测的考量
该研究基于1987至2014年接受根治性前列腺切除术的8,095例活检分级分组1或2且符合NCCN低风险定义(PSA<10 ng/ml且cT2a或以下)的前列腺癌患者,比较有利风险分级分组2与低风险分级分组1的病理和肿瘤学结局。结果显示分级分组2与更高的非器官局限疾病风险(OR 3.1, 95%CI 1.7-5.7, p<0.001)及更差的10年生化复发和无系统进展生存相关。考虑主动监测的有利风险分级分组2患者应被告知不良病理特征的风险及其对后续治疗和癌症进展的影响。
要点
- 活检分级分组2且其他特征有利的患者非器官局限疾病风险约为分级分组1的3.1倍(OR 3.1, 95%CI 1.7-5.7, p<0.001)。
- 分级分组2 vs 1的10年生化复发无生存率为81.2% vs 88.9%,10年无系统进展生存率为96.5% vs 99%(均p<0.001)。
- 分级分组2患者接受晚期激素治疗(术后>90天)和放疗的比例分别为8.5%和12.2%,高于分级分组1的3.1%和6.0%(p<0.001)。
核心结论
- 考虑主动监测的有利风险分级分组2患者应被告知不良病理特征风险及其对二次治疗和癌症进展的影响。
研究设计与样本
- 查询前瞻性维护的根治性前列腺切除术数据库,纳入1987至2014年接受手术的8,095例活检分级分组1或2且符合NCCN低风险定义(PSA<10 ng/ml且cT2a或以下)的患者。
- 采用多变量逻辑回归和Kaplan-Meier方法比较病理和肿瘤学结局。
主要发现
- 器官局限疾病在分级分组1和有利中间风险分级分组2中分别占93.9%和82.6%,精囊侵犯分别占1.7%和4.7%,淋巴结病变分别占0.3%和1.8%(均p<0.0001)。
- 多变量逻辑回归显示活检证实分级分组2疾病与非器官局限疾病风险增加三倍相关(OR 3.1, 95%CI 1.7-5.7, p<0.001)。
- 分级分组1 vs 2的晚期治疗(术后>90天)发生率:激素治疗3.1% vs 8.5%,放疗6.0% vs 12.2%(p<0.001)。
- 分级分组1 vs 2的10年生化复发无生存率为88.9% vs 81.2%,10年无系统进展生存率为99% vs 96.5%(均p<0.001)。
关键数值与推荐
- NCCN低风险定义:PSA<10 ng/ml且cT2a或以下。
- 活检分级分组2且其他特征有利的患者为主动监测候选者(根据NCCN指南)。
临床怎么用
- 对于有利风险分级分组2且考虑主动监测的患者,应告知其不良病理特征风险及对二次治疗和癌症进展的影响。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Recent NCCN® (National Comprehensive Cancer Network®) Guidelines® show that patients with biopsy Gleason score 3 + 4/Grade Group 2 but otherwise favorable features are active surveillance candidates. However, little is known about the long-term outcomes compared to that in men in the low risk Gleason score 6/Grade Group 1 group. We sought to clarify the risk of adverse features and oncologic outcomes in surgically treated, favorable Grade Group 2 vs 1 cases. MATERIALS AND METHODS: We queried our prospectively maintained radical prostatectomy database for all 8,095 patients with biopsy Grade Group 1 or 2 prostate cancer who otherwise fulfilled the NCCN low risk definition of prostate specific antigen less than 10 ng/ml and cT2a or less, and who underwent radical prostatectomy from 1987 to 2014. Multivariable logistic regression and Kaplan-Meier methods were used to compare pathological and oncologic outcomes. RESULTS: Organ confined disease was present in 93.9% and 82.6% of Grade Group 1 and favorable intermediate risk Grade Group 2 cases while seminal vesicle invasion was noted in 1.7% and 4.7%, and nodal disease was noted in 0.3% and 1.8%, respectively (all p <0.0001). On multivariable logistic regression biopsy proven Grade Group 2 disease was associated with a threefold greater risk of nonorgan confined disease (OR 3.1, 95% CI 1.7-5.7, p <0.001). The incidence of late treatment (more than 90 days from surgery) in Grade Group 1 vs 2 was 3.1% vs 8.5% for hormonal therapy and 6.0% vs 12.2% for radiation (p <0.001). In the Grade Group 1 vs 2 cohorts the 10-year biochemical recurrence-free survival rate was 88.9% vs 81.2% and the 10-year systemic progression-free survival rate was 99% vs 96.5% (each p <0.001). CONCLUSIONS: Men at favorable risk with Grade Group 2 disease who are considering active surveillance should be informed of the risks of harboring adverse pathological features which impact secondary therapies and an increased risk of cancer progression.
引用
- Gearman DJ, Morlacco A, Cheville JC, et al. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance. J Urol. 2017. PMID: 29225057. doi:10.1016/j.juro.2017.11.116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。